A FAAH Inhibitor Disrupted Liver Endocannabinoid Balance and Increased Oxidative Stress in Hypertensive Rats | Research

The takeaway

Chronic administration of the FAAH inhibitor URB597 to hypertensive rats further increased endocannabinoid levels and CB1 receptors in the liver, but worsened oxidative stress and reduced antioxidant defenses.

Researchers interested in endocannabinoid system manipulation and its effects on organ health in disease states.

FAAH inhibition worsened liver oxidative stress in hypertensive rats despite anti-inflammatory effects

What the researchers found

Researchers tested whether URB597, a FAAH inhibitor that increases anandamide levels, could help or harm liver health in rats with salt-induced hypertension.

Hypertension itself already elevated endocannabinoid levels (anandamide, 2-AG, and NADA) and CB1 receptors while increasing oxidative stress and decreasing antioxidant capacity in the liver.

Adding URB597 further increased anandamide, NADA, and CB1 receptor levels. Rather than being protective, this additional endocannabinoid elevation decreased vitamin E and C levels, reduced antioxidant enzyme activities, lowered the protective transcription factor Nrf2, and increased oxidative damage to lipids, DNA, and proteins. The one positive effect was reduced inflammatory response.

Why it matters

FAAH inhibitors are being explored as potential therapeutics for various conditions. This study reveals an important caution: boosting endocannabinoid levels in the liver of hypertensive animals worsened oxidative stress despite reducing inflammation, highlighting the complexity of the endocannabinoid system in disease states.

The numbers in context

Hypertension increased AEA, 2-AG, NADA, and CB1 levels. URB597 further increased AEA, NADA, and CB1. URB597 decreased vitamin E, vitamin C, glutathione peroxidase, glutathione reductase, and Nrf2 expression. Oxidative modifications to lipids, DNA, and proteins were increased. Inflammatory response was reduced.

How the study worked

DOCA-salt hypertensive rats received chronic URB597 treatment. Liver tissue was analyzed for endocannabinoid levels, receptor expression, enzyme activities, antioxidant markers, oxidative modifications of lipids/DNA/proteins, transcription factor expression, and inflammatory markers.

What this study cannot tell us

This was an animal study using a specific model of hypertension (DOCA-salt), which may not represent all forms of hypertension. Only liver tissue was examined. Chronic dosing protocols in rats may not reflect potential human therapeutic regimens. The study assessed biochemical markers rather than functional liver outcomes.

How to read the evidence

This is an animal study examining one organ in one disease model. It provides mechanistic insight but has limited direct clinical applicability.

When this study was published

Published in 2016. Research on FAAH inhibitors has continued, with some clinical trials in humans.

The bigger picture

This study illustrates that the endocannabinoid system's effects are highly context-dependent. What might be therapeutic in one setting can be harmful in another, particularly in organs already under oxidative stress from conditions like hypertension.

Questions still open

Would FAAH inhibition have different effects in the liver of normotensive animals? Could combining a FAAH inhibitor with antioxidant supplementation prevent the oxidative damage while preserving anti-inflammatory benefits?

Common questions

Does this mean FAAH inhibitors are dangerous?

Not necessarily. This study examined a specific context: the liver of hypertensive rats. The effects of FAAH inhibition may differ in healthy organisms, in other organs, or in other disease states. However, it highlights that boosting endocannabinoid levels is not universally beneficial.

What is oxidative stress?

Oxidative stress occurs when the body produces more reactive oxygen species (free radicals) than its antioxidant defenses can handle. This leads to damage to cell membranes (lipids), DNA, and proteins, which can contribute to disease progression.

Read the original research

Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats.

Toxicology and applied pharmacology, 301, 31-41

View on PubMed ↗Publisher’s paper ↗

Citation

Biernacki, Michał; Łuczaj, Wojciech; Gęgotek, Agnieszka; Toczek, Marek; Bielawska, Katarzyna; Skrzydlewska, Elżbieta. (2016). Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats.. Toxicology and applied pharmacology, 301, 31-41. https://doi.org/10.1016/j.taap.2016.04.006